Even in localized stages of non-small cell lung cancer, which are amenable
to curative surgery, prognosis has remained disappointing over the last dec
ades. Thus, in these tumor stages, adjuvant therapy strategies are discusse
d. In the last decade, numerous prognostic factors have been investigated,
which might select patients for additional treatment. In this review, the p
rognostic impact of individual tumor cell dissemination, tumor cell prolife
ration, apoptosis, several parameters of angiogenesis (microvessel density,
VEGF, bFGF, VEGF receptors), p53, bcl-2, ras, p27(Kip1), erbB-2, telomeras
e as well as the retinoblastoma tumor suppressor gene is analysed. Up to no
w, none of these factors has gained a sufficient selectivity to serve as an
exclusive discriminator for adjuvant therapy. Nevertheless, a combination
of several parameters might contribute to characterize patient subgroups wi
th localized non-small cell lung cancer at high risk for distant relapse. (
C) 2001 Elsevier Science Ireland Ltd. All rights reserved.